To address this gap, we performed a comprehensive literature review incorporating multiple relevant clinical studies and applied meta-analysis methods to systematically evaluate the correlations between ERCC2 Lys751Gln, Asp312Asn, and Arg156Arg SNP and the risk of cervical cancer, endometrial cancer, and ovarian cancer. Here, ERCC2 is linked to ovarian carcinoma.